




<b>Name</b>	Sang Myung Woo	
<b>Country</b>	Korea, Republic of	
<b>Organization</b>	Center for Liver and Pancreatobiliary Cancer, National Cancer Center	
<b>Current Position</b>	Head, Program for Immunotherapy, Chief, Biomedicine Production Branch, Chief scientist, Division of Tumor Immunology. Staff physician, Center for Liver and Pancreatobiliary Cancer, Adjuvant associate professor, Graduate School of Cancer Science and Policy, National Cancer Center, Korea	

### Educational Background

1998	M.D., Seoul National University College of Medicine, Korea
2008	M.S., Seoul National University, Korea
2013	Ph.D., Dongguk University, Korea

### Professional Experiences

1998 – 1999	Medical Internship, Seoul National University Hospital, Korea
1999 – 2003	Residency in Internal Medicine, Seoul National University Hospital, Korea
2003 – 2006	Medical Officer in the Republic of Korea Air force
2006 – 2008	Research Fellow, Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Korea
2008- Present	Staff Physician, Center for Liver Cancer, National Cancer Center, Korea
2013-2014	Visiting Scholar, Department of Pathology, School of Medicine, UC San Diego
2014- 2017	Senior Scientist, Research Institute, National Cancer Center, Korea
2015- Present	Ajuvant Associate Professor, Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Korea

### Professional Organizations

2019~ Head, Program for Immunotherapy,  
2017~Chief, Biomedicine Production Branch,  
2019~ Chief scientist, Division of Tumor Immunology.  
2008~ Staff physician, Center for Liver and Pancreatobiliary Cancer,  
2017~ Adjuvant associate professor, Graduate School of Cancer Science and Policy, National Cancer Center, Korea

### Main Scientific Publications

2019 Cytopathological results of initial endoscopic ultrasound-guided fine needle aspiration for primary mass and prognosis in pancreatic cancer patients: *Cytopathology*. 30(2):173~178 (

2019 Effect of Early Management on Pain and Depression in Patients with Pancreatobiliary Cancer: A Randomized Clinical Trial: *CANCERS*. 11(1):E79~E79

2018 Somatic Mutations from Whole Exome Sequencing Analysis of the Patients with Biliary Tract Cancer: *GENOMICS & INFORMATICS*. 16(4):e35~e35

2018 Prospective Multicenter Study on the Challenges Inherent to Using Large Cell-Type Stents for Bilateral Stent-in-Stent Placement in Patients with Inoperable Malignant Hilar Biliary Obstruction: *Gut and Liver*. 12(6):722~727

2018 Effectiveness and feasibility of concurrent chemoradiotherapy using simultaneous integrated



- boostintensity modulated radiotherapy with and without induction chemotherapy for locally advanced pancreatic cancer: *Radiation Oncology Journal*. 36(3):200~209
- 2018 Individualized metabolic profiling stratifies pancreatic and biliary tract cancer: a useful tool for innovative screening programs and predictive strategies in healthcare: *EPMA Journal*. 9(3):287~297
- 2018 Incidence of Diabetes After Cancer Development : A Korean National Cohort Study: *JAMA oncology*. 4(8):1099~1105
- 2018 Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer: *Technology in cancer research & treatment*. 17:1~9
- 2018 3D Culture Protocol for Testing Gene Knockdown Efficiency and Cell Line Derivation: *Bio-protocol*. 8(11):e2874~e2874
- 2018 Favorable glycemic response after pancreatoduodenectomy in both patients with pancreatic cancer and patients with non-pancreatic cancer: *Medicine*. 97(18):e0590~e0590
- 2018 Prognostic implications of multiplex detection of KRAS mutations in cell-free DNA from patients with pancreatic ductal adenocarcinoma: *Clinical chemistry*. 64(4):726~734
- 2017 Clinical multi-omics strategies for the effective cancer management: *Journal of Proteomics*. 188:97~106
- 2017 Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer.: *Cancer Research and Treatment*. 50(3):883~893
- 2017 Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma: *Oncotarget*. 9(3):4034~4043
- 2017 Reduced levels of N<sup>7</sup>-methyl-2-pyridone-5-carboxamide and lysophosphatidylcholine 16:0 in the serum of patients with intrahepatic cholangiocarcinoma, and the correlation with recurrence-free survival: *Oncotarget*. 8(68):112598~112609
- 2017 DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study: *oncotarget*. 8(46):81394~81404
- 2017 Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study: *Cancer Research and Treatment*. Online:Published
- 2016 Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumor- A Retrospective Nationwide Multicenter Study in South Korea: *Pancreas*. 45(7):941~946
- 2016 Reintervention for occluded metal stent in malignant bile duct obstruction: a prospective randomized trial comparing covered and uncovered metal stent: *JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY*. Online:Published
- 2016 Development and Validation of a Prediction Model to Estimate Individual Risk of Pancreatic Cancer: *PloS one*. 11(1):e0146473~e0146473
- 2015 Postoperative CA19-9 Change Is a Useful Predictor of Intrahepatic Cholangiocarcinoma Survival following Liver Resection: *Disease Markers*. 2015:298985~298985
- 2015 Prognostic indicators for radiotherapy of abdominal lymph node metastases from hepatocellular carcinoma: *Strahlentherapie und Onkologie*. 191(11):835~844
- 2015 Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer: *Oncology*. Online:Published
- 2015 Small Cell Versus Large Cell-Sized Metal Stent in Endoscopic Bilateral Stent-in-Stent Placement for Malignant Hilar Biliary Obstruction1: *Digestive endoscopy*. 27(6):692~699
- 2014 Gemcitabine plus Cisplatin versus Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Cohort Study. *Chemotherapy*. 59(3): 232-238
- 2014 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line



- Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy. *Chemotherapy*. 59(4):232-238
- 2013 Efficacy of argon plasma coagulation in the treatment of radiation-induced hemorrhagic gastroduodenal vascular ectasia. *Scandinavian Journal of Gastroenterology*. 49(2):238-245
- 2013 Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer. *Radiation Oncology*. 8(1):160
- 2013 A Multicenter Phase II Trial of Gemcitabine Plus Oxaliplatin in Unresectable Gallbladder Cancer. *Gut and Liver* 7(5):594-598
- 2013 Outcomes of Concurrent Chemoradiotherapy versus Chemotherapy Alone for Advanced-stage Unresectable Intrahepatic Cholangiocarcinoma. *Radiation Oncology*. 21(8): 292
- 2013 Comparison of uncovered and covered stents for the treatment of malignant duodenal obstruction caused by pancreaticobiliary cancer: *Surgical Endoscopy*. 27(6):2031-2039
- 2013 Appropriate indications of initial endoscopic ultrasound evaluation for detecting mural nodules in branch duct intraductal papillary mucinous neoplasms of the pancreas. *Scandinavian Journal of Gastroenterology*. 48(5):610-616
- 2013 Risk of Pancreatic Cancer in Relation to ABO Blood Group and Hepatitis C Virus Infection in Korea: A Case-Control Study. *Journal of Korean Medical Science*. 28(2):247-251
- 2012 New Strategy in Cases of Failed Endoscopic Intervention of Biliary Strictures after Living Donor Liver Transplantation: Percutaneous Transhepatic Biliary Stent Insertion and Subsequent Endoscopic Treatment: *The Journal of the Korean Society for Transplantation*. 26(3):188~195
- 2012 Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Single-Center Study: *Chemotherapy*. 58(3):225~232
- 2012 Patterns of Initial Disease Recurrence after Resection of Biliary Tract Cancer: *Oncology*. 83(2):83~90
- 2012 Multiple Primary Malignant Neoplasms in Pancreatic Cancer Patients: A Single-Center Experience in Korea: *Pancreas*. 41(4):648~649
- 2012 Prostate Stem Cell Antigen, a Presumable Organ-Dependent Tumor Suppressor Gene, Is Down-Regulated in Gallbladder Carcinogenesis: *Genes, Chromosomes & Cancer*. 51(1):30~41
- 2011 CA 19-9 Level as Indicator of Early Distant Metastasis and Therapeutic Selection in Resected Pancreatic Cancer. *International Journal of Radiation Oncology, Biology, Physics*. 81:743~748
- 2011 Role of Adjuvant Chemoradiotherapy for Resected Extrahepatic Biliary Tract Cancer.: *International journal of radiation oncology, biology, physics*. 81:853~859
- 2011 Clinical features of 20 patients with curatively resected biliary neuroendocrine tumours: *Digestive and Liver Disease*. 43(12):965~970
- 2011 Pretreatment Carbohydrate Antigen 19-9 Level Indicates Tumor Response, Early Distant Metastasis, Overall Survival, and Therapeutic Selection in Localized and Unresectable Pancreatic Cancer.: *International journal of radiation oncology, biology, physics*. 81:623~630
- 2011 Effects and Mechanisms of the Combination of Suberoylanilide Hydroxamic Acid and Bortezomib on the Anticancer Property of Gemcitabine in Pancreatic Cancer. *Pancreas*. 40(6):966~973
- 2010 Endoscopic management of occluded metal biliary stents: Metal versus 10F plastic stents: *World Journal of Gastroenterology*. 14:5347~5352
- 2010 Adjuvant Chemoradiation Therapy in Gallbladder Cancer: *Journal of Surgical Oncology*. 102(1):87~93
- 2010 Survival Analysis of Intrahepatic Cholangiocarcinoma After Resection: *Annals of Surgical Oncology*. 17(7):1823~1830
- 2009 A comparison of the Niti-D biliary uncovered stent and the uncovered Wallstent in malignant biliary obstruction. *Gastrointestinal endoscopy*. 70:45~51